Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells

Takeshi Kiriyama, Sumiaki Okamoto, Eri Ejima, Noriyoshi Kurihara, Yoshiro Hakeda, Nobuhiro Ito, Motomori Izumi, Masayoshi Kumegawa, Sigenobu Nagataki

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The fluorine introduced analog of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 [26,27-F6-1,25-(OH)2D3] is 5-10 times more potent than 1,25-(OH)2D3 in vitamin D-deficient rats and chicks. In this study we established cultures of human bone cells in order to elucidate the mechanisms responsible for the higher activity of this compound. The effects of 26,27-F6-1,25-(OH)2D3 and 26,26,26,27,27,27-hexafluoro-1,23(S),25-trihydroxyvitamin D3[26,27-F6-1,23(S),25-(OH)3D3], the postulated main metabolite of 26,27-F6-1,25-(OH)2D3, were assessed by the response of alkaline phosphatase (ALP) activity. 26,27-F6-1,25-(OH)2D3 increased ALP activity in a dose-related fashion, from a concentration of 10-11 M and caused a 3-fold elevation at a concentration of 10-9 M. To achieve the same stimulating effect on ALP activity, the required dose of 26,27-F6-1,25-(OH)2D3 was 100 times less than that of 1,25-(OH)2D3. Analysis of the receptors of these cells revealed that they have specific receptors for 1,25-(OH)2D3, which have a dissociation constant of 0.9 X 10-10 M. The competitive binding assays of 26,27-F6-1,25-(OH)2D3 on these receptors showed that binding ability of 26,27-F6-1,25-(OH)2D3 is almost the same as that of 1,25-(OH)2D3. Therefore, receptor binding affinity does not account for the higher potency of 26,27-F6-1,25-(OH)2D3. The trihydroxylated compound, 26,27-F6-1,23(S),25-(OH)3D3 revealed almost the same stimulatory activity on ALP activity in these cells. The most likely explanation for the higher activity of 26,27-F6-1,25-(OH)2D3 than 1,25-(OH)2D3 is that 26,27-F6-1,25-(OH)2D3 is metabolized to 26,27-F6-1,23(S),25-(OH)3D3, which has almost the same activity as 26,27-F6-1,25-(OH)2D3 in target tissues, whereas 1,25-(OH)2D3 is degraded to less active metabolites such as 1,24,25-(OH)3D3.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalEndocrinology
Volume128
Issue number1
StatePublished - Jan 1991
Externally publishedYes

Fingerprint

Calcitriol
Bone and Bones
Alkaline Phosphatase
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3
Competitive Binding
Fluorine
Vitamin D

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Kiriyama, T., Okamoto, S., Ejima, E., Kurihara, N., Hakeda, Y., Ito, N., ... Nagataki, S. (1991). Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinology, 128(1), 81-86.

Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. / Kiriyama, Takeshi; Okamoto, Sumiaki; Ejima, Eri; Kurihara, Noriyoshi; Hakeda, Yoshiro; Ito, Nobuhiro; Izumi, Motomori; Kumegawa, Masayoshi; Nagataki, Sigenobu.

In: Endocrinology, Vol. 128, No. 1, 01.1991, p. 81-86.

Research output: Contribution to journalArticle

Kiriyama, T, Okamoto, S, Ejima, E, Kurihara, N, Hakeda, Y, Ito, N, Izumi, M, Kumegawa, M & Nagataki, S 1991, 'Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells', Endocrinology, vol. 128, no. 1, pp. 81-86.
Kiriyama T, Okamoto S, Ejima E, Kurihara N, Hakeda Y, Ito N et al. Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinology. 1991 Jan;128(1):81-86.
Kiriyama, Takeshi ; Okamoto, Sumiaki ; Ejima, Eri ; Kurihara, Noriyoshi ; Hakeda, Yoshiro ; Ito, Nobuhiro ; Izumi, Motomori ; Kumegawa, Masayoshi ; Nagataki, Sigenobu. / Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. In: Endocrinology. 1991 ; Vol. 128, No. 1. pp. 81-86.
@article{e9d246c3aefc4f8eb730a6531d7349a5,
title = "Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells",
abstract = "The fluorine introduced analog of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 [26,27-F6-1,25-(OH)2D3] is 5-10 times more potent than 1,25-(OH)2D3 in vitamin D-deficient rats and chicks. In this study we established cultures of human bone cells in order to elucidate the mechanisms responsible for the higher activity of this compound. The effects of 26,27-F6-1,25-(OH)2D3 and 26,26,26,27,27,27-hexafluoro-1,23(S),25-trihydroxyvitamin D3[26,27-F6-1,23(S),25-(OH)3D3], the postulated main metabolite of 26,27-F6-1,25-(OH)2D3, were assessed by the response of alkaline phosphatase (ALP) activity. 26,27-F6-1,25-(OH)2D3 increased ALP activity in a dose-related fashion, from a concentration of 10-11 M and caused a 3-fold elevation at a concentration of 10-9 M. To achieve the same stimulating effect on ALP activity, the required dose of 26,27-F6-1,25-(OH)2D3 was 100 times less than that of 1,25-(OH)2D3. Analysis of the receptors of these cells revealed that they have specific receptors for 1,25-(OH)2D3, which have a dissociation constant of 0.9 X 10-10 M. The competitive binding assays of 26,27-F6-1,25-(OH)2D3 on these receptors showed that binding ability of 26,27-F6-1,25-(OH)2D3 is almost the same as that of 1,25-(OH)2D3. Therefore, receptor binding affinity does not account for the higher potency of 26,27-F6-1,25-(OH)2D3. The trihydroxylated compound, 26,27-F6-1,23(S),25-(OH)3D3 revealed almost the same stimulatory activity on ALP activity in these cells. The most likely explanation for the higher activity of 26,27-F6-1,25-(OH)2D3 than 1,25-(OH)2D3 is that 26,27-F6-1,25-(OH)2D3 is metabolized to 26,27-F6-1,23(S),25-(OH)3D3, which has almost the same activity as 26,27-F6-1,25-(OH)2D3 in target tissues, whereas 1,25-(OH)2D3 is degraded to less active metabolites such as 1,24,25-(OH)3D3.",
author = "Takeshi Kiriyama and Sumiaki Okamoto and Eri Ejima and Noriyoshi Kurihara and Yoshiro Hakeda and Nobuhiro Ito and Motomori Izumi and Masayoshi Kumegawa and Sigenobu Nagataki",
year = "1991",
month = "1",
language = "English (US)",
volume = "128",
pages = "81--86",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells

AU - Kiriyama, Takeshi

AU - Okamoto, Sumiaki

AU - Ejima, Eri

AU - Kurihara, Noriyoshi

AU - Hakeda, Yoshiro

AU - Ito, Nobuhiro

AU - Izumi, Motomori

AU - Kumegawa, Masayoshi

AU - Nagataki, Sigenobu

PY - 1991/1

Y1 - 1991/1

N2 - The fluorine introduced analog of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 [26,27-F6-1,25-(OH)2D3] is 5-10 times more potent than 1,25-(OH)2D3 in vitamin D-deficient rats and chicks. In this study we established cultures of human bone cells in order to elucidate the mechanisms responsible for the higher activity of this compound. The effects of 26,27-F6-1,25-(OH)2D3 and 26,26,26,27,27,27-hexafluoro-1,23(S),25-trihydroxyvitamin D3[26,27-F6-1,23(S),25-(OH)3D3], the postulated main metabolite of 26,27-F6-1,25-(OH)2D3, were assessed by the response of alkaline phosphatase (ALP) activity. 26,27-F6-1,25-(OH)2D3 increased ALP activity in a dose-related fashion, from a concentration of 10-11 M and caused a 3-fold elevation at a concentration of 10-9 M. To achieve the same stimulating effect on ALP activity, the required dose of 26,27-F6-1,25-(OH)2D3 was 100 times less than that of 1,25-(OH)2D3. Analysis of the receptors of these cells revealed that they have specific receptors for 1,25-(OH)2D3, which have a dissociation constant of 0.9 X 10-10 M. The competitive binding assays of 26,27-F6-1,25-(OH)2D3 on these receptors showed that binding ability of 26,27-F6-1,25-(OH)2D3 is almost the same as that of 1,25-(OH)2D3. Therefore, receptor binding affinity does not account for the higher potency of 26,27-F6-1,25-(OH)2D3. The trihydroxylated compound, 26,27-F6-1,23(S),25-(OH)3D3 revealed almost the same stimulatory activity on ALP activity in these cells. The most likely explanation for the higher activity of 26,27-F6-1,25-(OH)2D3 than 1,25-(OH)2D3 is that 26,27-F6-1,25-(OH)2D3 is metabolized to 26,27-F6-1,23(S),25-(OH)3D3, which has almost the same activity as 26,27-F6-1,25-(OH)2D3 in target tissues, whereas 1,25-(OH)2D3 is degraded to less active metabolites such as 1,24,25-(OH)3D3.

AB - The fluorine introduced analog of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 [26,27-F6-1,25-(OH)2D3] is 5-10 times more potent than 1,25-(OH)2D3 in vitamin D-deficient rats and chicks. In this study we established cultures of human bone cells in order to elucidate the mechanisms responsible for the higher activity of this compound. The effects of 26,27-F6-1,25-(OH)2D3 and 26,26,26,27,27,27-hexafluoro-1,23(S),25-trihydroxyvitamin D3[26,27-F6-1,23(S),25-(OH)3D3], the postulated main metabolite of 26,27-F6-1,25-(OH)2D3, were assessed by the response of alkaline phosphatase (ALP) activity. 26,27-F6-1,25-(OH)2D3 increased ALP activity in a dose-related fashion, from a concentration of 10-11 M and caused a 3-fold elevation at a concentration of 10-9 M. To achieve the same stimulating effect on ALP activity, the required dose of 26,27-F6-1,25-(OH)2D3 was 100 times less than that of 1,25-(OH)2D3. Analysis of the receptors of these cells revealed that they have specific receptors for 1,25-(OH)2D3, which have a dissociation constant of 0.9 X 10-10 M. The competitive binding assays of 26,27-F6-1,25-(OH)2D3 on these receptors showed that binding ability of 26,27-F6-1,25-(OH)2D3 is almost the same as that of 1,25-(OH)2D3. Therefore, receptor binding affinity does not account for the higher potency of 26,27-F6-1,25-(OH)2D3. The trihydroxylated compound, 26,27-F6-1,23(S),25-(OH)3D3 revealed almost the same stimulatory activity on ALP activity in these cells. The most likely explanation for the higher activity of 26,27-F6-1,25-(OH)2D3 than 1,25-(OH)2D3 is that 26,27-F6-1,25-(OH)2D3 is metabolized to 26,27-F6-1,23(S),25-(OH)3D3, which has almost the same activity as 26,27-F6-1,25-(OH)2D3 in target tissues, whereas 1,25-(OH)2D3 is degraded to less active metabolites such as 1,24,25-(OH)3D3.

UR - http://www.scopus.com/inward/record.url?scp=0025979024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025979024&partnerID=8YFLogxK

M3 - Article

VL - 128

SP - 81

EP - 86

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -